Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT

• Published in: Blood 2019-02, Vol.133 (9), p.978-989
• Main Authors: Krauel, Krystin, Preuße, Patricia, Warkentin, Theodore E., Trabhardt, Catja, Brandt, Sven, Jensch, Inga, Mandelkow, Martin, Hammer, Elke, Hammerschmidt, Sven, Greinacher, Andreas
• Format: Article
• Language: English
• Subjects: Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - metabolism; Anticoagulants; Blood Platelets - immunology; Blood Platelets - metabolism; Case-Control Studies; Fibronectins - immunology; Fibronectins - metabolism; Heparin - adverse effects; Heparin - immunology; Humans; Platelet Activation; Platelet Factor 4 - immunology; Platelet Factor 4 - metabolism; Prognosis; Thrombocytopenia - chemically induced; Thrombocytopenia - immunology; Thrombocytopenia - pathology
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2018-05-850370

Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating anti–platelet factor 4 (PF4)/heparin antibodies. Platelet activation assays that use “washed” platelets are more sensitive for detecting HIT antibodies than platelet-rich plasma (PRP)–based assays. Moreover, heparin-exposed patients vary considerably with respect to the risk of PF4/heparin immunization and, among antibody-positive patients, the risk of subsequent “breakthrough” of clinical HIT with manifestation of thrombocytopenia. We used washed platelets and PRP, standard laboratory HIT tests, and physicochemical methods to identify a plasma factor interfering with PF4/heparin complexes and anti-PF4/heparin antibody–platelet interaction, thus explaining differences in functional assays. To investigate a modulating risk for PF4/heparin immunization and breakthrough of HIT, we also tested 89 plasmas from 2 serosurveillance trials. Fibronectin levels were measured in 4 patient groups exhibiting different degrees of heparin-dependent immunization and expression of HIT. The heat-labile plasma protein, fibronectin, inhibited PF4 binding to platelets in a dose-dependent fashion, particularly in washed (vs PRP) systems. Fibronectin also inhibited PF4/heparin binding to platelets, anti-PF4/heparin antibody binding to PF4/heparin complexes, and anti-PF4/heparin antibody–induced platelet activation as a result of PF4/heparin complex disruption. In addition, plasma fibronectin levels increased progressively among the following 4 patient groups: enzyme-linked immunosorbent assay (ELISA)+/serotonin-release assay (SRA)+/HIT+ < ELISA+/SRA+/HIT− ∼ ELISA+/SRA−/HIT− < ELISA−/SRA−/HIT−. Altogether, these findings suggest that fibronectin interferes with PF4/heparin complex formation and anti-PF4/heparin antibody–induced platelet activation. Reduced fibronectin levels in washed platelet assays help to explain the greater sensitivity of washed platelet (vs PRP) assays for HIT. More importantly, lower plasma fibronectin levels could represent a risk factor for PF4/heparin immunization and clinical breakthrough of HIT. •Fibronectin disrupts PF4/heparin complexes and inhibits anti-PF4/heparin antibody–mediated platelet activation in vitro.•Low plasma fibronectin is associated with increased anti-PF4/heparin antibody formation and increased breakthrough of HIT. [Display omitted]